The ILKAP Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-mediated gene-disrupted population of HeLa cervical adenocarcinoma cells, engineered to introduce loss-of-function mutations throughout the ILKAP gene. This polyclonal pool comprises a heterogeneous population of edited cells, avoiding clonal artifacts and providing a biologically robust model to study ILKAP deficiency. As a polyclonal knockout product, it is particularly suited for experiments where population-level effects of gene disruption are analyzed, such as signaling pathway interrogation and functional assays.
HeLa cells are a well-established human cervical adenocarcinoma cell line with epithelial adherent morphology. The cell line is HPV-18 positive and expresses the E6 and E7 oncoproteins, which inactivate the tumor suppressors p53 and Rb, respectively. These genetic aberrations create a permissive background for studying oncogenic signaling networks, integrin-mediated adhesion, and pathways frequently dysregulated in cancer. The HeLa model is widely employed in signal transduction research and drug discovery due to its rapid proliferation and ease of genetic manipulation.
ILKAP encodes a Mg2+/Mn2+-dependent serine/threonine phosphatase that functions as a key negative regulator of integrin-linked kinase (ILK) signaling. Upon integrin engagement, ILKAP is recruited to the ILK/PINCH/PARVA complex, where it dephosphorylates ILK at its activation loop, thereby inhibiting ILK kinase activity. This event reduces the phosphorylation of downstream effectors including AKT1 and GSK3B. Consequently, GSK3B remains active and promotes phosphorylation-dependent degradation of ??-catenin (CTNNB1), leading to attenuated TCF/LEF-mediated transcription of Wnt target genes such as CCND1. ILKAP activity is regulated by upstream cues including TGF-?? signaling and potentially by p53-dependent transcriptional control, while its interacting partners include ILK, PINCH1, PARVA, and RSU1. Representative pathway components that impinge on this network include ITGB1, ITGA5, ILK, AKT1, GSK3B, CTNNB1, and TCF/LEF transcription factors.
In the context of HeLa cells, loss of ILKAP is expected to relieve the inhibitory constraint on ILK, resulting in enhanced ILK-mediated phosphorylation of AKT and GSK3??. This leads to stabilization and nuclear accumulation of ??-catenin, which drives the expression of pro-proliferative and pro-migratory genes. Given that HeLa cells already harbor inactivated p53 and Rb, ILKAP disruption may synergistically amplify oncogenic signaling, making this knockout model a powerful tool for studying tumor progression and metastasis. Additionally, the polyclonal nature of the product allows for assessment of heterogeneous cellular responses that better mimic the genomic diversity seen in solid tumors, thereby supporting translational cancer research.
This knockout cell population is suitable for a wide range of investigational applications, including dissection of integrin signal transduction, validation of ILKAP as a potential tumor suppressor, and drug target screening. Researchers can employ Western blotting to monitor phosphorylated levels of ILK, AKT (p-AKT1), and GSK3??, as well as ??-catenin/TCF luciferase reporter assays to quantify Wnt pathway activity. Co-immunoprecipitation can be used to assess ILKAP-ILK complex formation, while immunofluorescence enables visualization of focal adhesion dynamics. Functional assays such as wound-healing migration, transwell invasion, and proliferation assays allow direct measurement of phenotypic consequences. For further experimental details and customization options, please contact Ascent Research.
